Finding 1215019 (2024-009)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2024
Accepted
2026-05-19

AI Summary

  • Core Issue: Unallowable administrative costs, specifically marketing and financing expenses, were improperly charged as direct expenses to UC grants.
  • Impacted Requirements: Costs must comply with federal regulations, specifically § 75.467 and § 200.449, which prohibit certain marketing and interest costs unless approved.
  • Recommended Follow-Up: Re-establish internal controls to ensure tracking of allowable expenditures and reconcile these with cash draws.

Finding Text

Finding: Unallowable administrative costs charged as direct expenses. Criteria: Allowable Costs/ Cost Principles (Non-profit Organization) Per the Code of Federal Regulations § 75.467 Selling and marketing costs., costs of selling and marketing any products or services of the non-Federal entity (unless allowed under § 75.421) are unallowable, except as direct costs, with prior approval by the HHS awarding agency when necessary for the performance of the Federal award. Per the Code of Federal Regulations § 200.449 Interest, costs incurred for interest on borrowed capital, temporary use of endowment funds, or the use of the recipient's or subrecipient's own funds are unallowable. Condition and Context, and Cause: During our audit, we identified unallowable marketing and financing expenditures allocated to the UC grants. See discussion above at 2024-006 for background on failure to track allowable costs. Result: Amounts identified as unallowable costs per the compliance guidance have been included in the contract liability as disclosed in Note 12. See the Summary of Unallowable Costs and Questioned Costs tables for detail on page 56. Recommendation: The auditors recommend the Organization re-implement internal controls to track allowable expenditures and reconcile qualifying costs with cash draws.

Corrective Action Plan

Cayuga Centers does not fully understand the scope of this asserted finding. It will, however, work with its auditors to fully assess this finding. As discussed above, Cayuga Centers has engaged grants management advisors who will assist in evaluating the scope of this asserted findings. To the extent that the costs referenced in this finding are unallowable, Cayuga Centers will address the matter with its primary funding agency as part of broader resolution of any unallowable costs. To the extent this finding asserts control failures, please see Cayuga Centers’ response to Findings 2024-005 and 006 above.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 1214969 2024-003
    Material Weakness Repeat
  • 1214970 2024-004
    Material Weakness Repeat
  • 1214971 2024-005
    Material Weakness Repeat
  • 1214972 2024-006
    Material Weakness Repeat
  • 1214973 2024-007
    Material Weakness Repeat
  • 1214974 2024-008
    Material Weakness Repeat
  • 1214975 2024-009
    Material Weakness Repeat
  • 1214976 2024-010
    Material Weakness Repeat
  • 1214977 2024-011
    Material Weakness Repeat
  • 1214978 2024-012
    Material Weakness Repeat
  • 1214979 2024-013
    Material Weakness Repeat
  • 1214980 2024-003
    Material Weakness Repeat
  • 1214981 2024-004
    Material Weakness Repeat
  • 1214982 2024-005
    Material Weakness Repeat
  • 1214983 2024-006
    Material Weakness Repeat
  • 1214984 2024-007
    Material Weakness Repeat
  • 1214985 2024-008
    Material Weakness Repeat
  • 1214986 2024-009
    Material Weakness Repeat
  • 1214987 2024-010
    Material Weakness Repeat
  • 1214988 2024-011
    Material Weakness Repeat
  • 1214989 2024-012
    Material Weakness Repeat
  • 1214990 2024-013
    Material Weakness Repeat
  • 1214991 2024-003
    Material Weakness Repeat
  • 1214992 2024-004
    Material Weakness Repeat
  • 1214993 2024-005
    Material Weakness Repeat
  • 1214994 2024-006
    Material Weakness Repeat
  • 1214995 2024-007
    Material Weakness Repeat
  • 1214996 2024-008
    Material Weakness Repeat
  • 1214997 2024-009
    Material Weakness Repeat
  • 1214998 2024-010
    Material Weakness Repeat
  • 1214999 2024-011
    Material Weakness Repeat
  • 1215000 2024-012
    Material Weakness Repeat
  • 1215001 2024-013
    Material Weakness Repeat
  • 1215002 2024-003
    Material Weakness Repeat
  • 1215003 2024-004
    Material Weakness Repeat
  • 1215004 2024-005
    Material Weakness Repeat
  • 1215005 2024-006
    Material Weakness Repeat
  • 1215006 2024-007
    Material Weakness Repeat
  • 1215007 2024-008
    Material Weakness Repeat
  • 1215008 2024-009
    Material Weakness Repeat
  • 1215009 2024-010
    Material Weakness Repeat
  • 1215010 2024-011
    Material Weakness Repeat
  • 1215011 2024-012
    Material Weakness Repeat
  • 1215012 2024-013
    Material Weakness Repeat
  • 1215013 2024-003
    Material Weakness Repeat
  • 1215014 2024-004
    Material Weakness Repeat
  • 1215015 2024-005
    Material Weakness Repeat
  • 1215016 2024-006
    Material Weakness Repeat
  • 1215017 2024-007
    Material Weakness Repeat
  • 1215018 2024-008
    Material Weakness Repeat
  • 1215020 2024-010
    Material Weakness Repeat
  • 1215021 2024-011
    Material Weakness Repeat
  • 1215022 2024-012
    Material Weakness Repeat
  • 1215023 2024-013
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.676 UNACCOMPANIED ALIEN CHILDREN PROGRAM $5.28M
93.959 BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE $260,463